Therapy Areas: Vaccines
Biosceptre reports launch of Phase 1 clinical trial of first-in-class oncology vaccine BIL06v
22 August 2018 -

UK biotechnology company Biosceptre International Limited said on Tuesday that the first cancer patient was treated at the Sydney Adventist Hospital in Sydney, Australia under the treating physician and principal investigator associate professor Gavin Marx in a Phase I clinical trial of the peptide vaccine BIL06v.

Additionally, other clinical sites will be included in the trial and competitive recruitment for the minimum six month treatment is anticipated to proceed to the full cohort (20-30) within 12 months, according to the company.

The company stated the trial will accept broad cancer indications with primary focus on prostate and lung cancer patients who are refractory to, or have refused, standard of care treatment. Breast, colorectal and other cancer patients will also be accepted.

This trial has been designed by Dr Bob Li, attending oncologist at the Memorial Sloan Kettering Cancer Center in New York. The trial will be overseen by the company's CMO Paul De Souza, who is foundation chair of Medical Oncology, School of Medicine, at Western Sydney University and honorary professor of the NHMRC Clinical Trials Centre, University of Sydney.

According to the company, BIL06v therapy is a peptide protein conjugate vaccine, administered in the presence of an adjuvant. The primary endpoints include evaluation of safety and immunogenicity, with secondary endpoints including dose limiting toxicity and/or maximum tolerated dose as well as recommended Phase II dose. Disease control rate at 12 weeks as well as progression free survival will also be examined. Exploratory endpoints will include quality of life and overall survival.

Login
Username:

Password: